Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors

被引：0
|
作者：
Li, Jin
Cao, Junning
Wang, Jin
Li, Baoyue
Chi, Haidong
Gao, Ling
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT158
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors.
    Liu, Yongheng
    Lian, Wei
    Zhao, Xi
    Qi, Wei
    Xu, Jian
    Xiao, Liang
    Qing, Yan
    Xue, Tongtong
    Wang, Jingyi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Radoimmunoimaging of a murine mammary carcinoma with a monoclonal antibody to vascular endothelial growth factor receptor-2
    Fiszman, Gabriel L.
    D'Orio, Ernesto G.
    Gongora, Adrian
    Mladovan, Alejandro
    Jasnis, Maria A.
    Baldi, Alberto
    CANCER RESEARCH, 2006, 66 (08)
  • [23] A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.
    Lee, Keun Wook
    Oh, Do-Youn
    Han, Sae-Won
    Kim, Jin Won
    Shin, Jung-Won
    Jo, Seong-Jin
    Kim, Na Hyung
    Woo, Ahmi
    Won, Jonghwa
    Hahn, Seokyung
    Lee, Howard
    Kim, Woo Ho
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis
    Higano, Celestia
    LoRusso, Patricia
    Gordon, Michael
    Yu, Evan Y.
    Whiting, Samuel H.
    Fox, Floyd
    Katz, Terry
    Rowinsky, Eric
    Youssoufian, Hagop
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3439S - 3439S
  • [25] Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor
    Vanhoefer, U
    Tewes, M
    Rojo, F
    Dirsch, O
    Schleucher, N
    Rosen, O
    Tillner, J
    Kovar, A
    Braun, AH
    Trarbach, T
    Seeber, S
    Harstrick, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 175 - 184
  • [26] Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors
    Wang, Chong
    He, Xiaohui
    Zhou, Bo
    Li, Jing
    Li, Bohua
    Qian, Weizhu
    Hou, Sheng
    Wang, Hao
    Shi, Yuankai
    Guo, Yajun
    MABS, 2011, 3 (01) : 67 - 75
  • [27] A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer.
    Camidge, D. R.
    Eckhardt, S. G.
    Diab, S.
    Gore, L.
    Chow, L.
    O'Bryant, C.
    Temmer, E.
    Ervin-Haynes, A.
    Katz, T.
    Fox, F.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 128S - 128S
  • [28] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [29] A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results.
    Kuenen, B.
    Witteveen, E.
    Ruijter, R.
    Ervin-Haynes, A.
    Tjin-A-ton, M.
    Fox, F.
    Ding, C.
    Giaccone, G.
    Voest, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 126S - 126S
  • [30] Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies
    Rothenberg, M. L.
    Poplin, E.
    LoRusso, P.
    Yu, E.
    Schwartz, J.
    Fox, F.
    Mehnert, J.
    Sandler, A. B.
    Rowinsky, E.
    Higano, C. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 174 - 175
12345